Peripheral regulatory T cells and serum transforming growth factor-β: relationship with clinical response to infliximab in Crohn's disease

Di Sabatino, Antonio, Biancheri, Paolo, Piconese, Silvia, Rosado, M Manuela, Ardizzone, Sandro, Rovedatti, Laura, Ubezio, Cristina, Massari, Alessandro, Sampietro, Gianluca M, Foschi, Diego, Porro, Gabriele Bianchi, Colombo, Mario P, Carsetti, Rita, MacDonald, Thomas T and Corazza, Gino R (2010) Peripheral regulatory T cells and serum transforming growth factor-β: relationship with clinical response to infliximab in Crohn's disease. Inflammatory Bowel Diseases, 16 (11). pp. 1891-1897. ISSN 1078-0998

Full text not available from this repository. (Request a copy)

Abstract

BACKGROUND: CD4(+)Foxp3(+) regulatory T cells (Treg) inhibit T-cell proliferation in vitro and are effective in suppressing colitis in mouse models. Tumor necrosis factor (TNF)-α, which is centrally involved in Crohn's disease (CD) pathogenesis, also impairs Treg function. Here we investigated the influence of anti-TNF therapy on Treg frequency and function in CD. METHODS: Twenty CD patients were treated with infliximab administered at weeks 0, 2, and 6. Blood was collected immediately before the first infusion and after 10 weeks. Treg frequency was quantified by flow cytometry. Treg function was measured using a standard coculture assay. Serum levels of transforming growth factor (TGF)-β1 and interleukin (IL)-10 were measured by enzyme-linked immunosorbent assay (ELISA). RESULTS: Pretreatment Treg frequency and serum TGF-β1 levels were significantly higher in nonresponder than responder patients. Clinical improvement in 12 CD patients was associated with a significant increase of Treg frequency after 10 weeks. Treg were functionally active before and after treatment with infliximab, both in responder and nonresponder CD patients. In responder patients the restoration of Treg pool was accompanied by a parallel significant increase of serum TGF-β1 and IL-10. No significant change in the elevated Treg or serum TGF-β1 was seen in nonresponder patients. CONCLUSIONS: This study suggests that there may be a relationship between numbers of Treg in the blood, serum TGF-β1, and response to infliximab; however, further prospective studies are needed.

Item Type: Article
Uncontrolled Keywords: adult,therapeutic use,blood,female,therapeutic use,humans,infliximab,blood,lymphocyte count,male,immunology,blood,young adult
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
University of East Anglia > Faculty of Medicine and Health Sciences > Research Groups > Gastroenterology and Gut Biology
Depositing User: LivePure Connector
Date Deposited: 07 Aug 2018 17:30
Last Modified: 07 Aug 2018 20:30
URI: https://ueaeprints.uea.ac.uk/id/eprint/67995
DOI: 10.1002/ibd.21271

Actions (login required)

View Item